Senores Pharmaceuticals Share Price Rises 3%; Launches Deferiprone Tablets in US Market

Senores Pharmaceuticals Limited has announced the US launch of Deferiprone Tablets USP, available in 500 mg and 1000 mg strengths. The product, bioequivalent to Chiesi USA’s Ferriprox Tablets, will be marketed by Dr. Reddy’s Laboratories. 

The launch targets a niche segment of the US market, reflecting the company’s focus on under-penetrated generic formulations with growth potential.

Product Launch and Market Potential

Deferiprone Tablets, 500 mg and 1000 mg, had annual US sales of approximately $70 million for the twelve months ending October 2025. The launch provides Senores an opportunity to expand its presence in the US generics market and address unmet healthcare needs.

Swapnil Shah, Managing Director of Senores Pharmaceuticals, stated that the launch aligns with the company’s strategy of focusing on limited-competition products and specialised generics.

Company Profile and Capabilities

Senores Pharmaceuticals operates globally, developing and manufacturing pharmaceuticals for regulated and emerging markets, including the US and Canada. Its current portfolio comprises 46 ANDAs and 133 strengths, with a pipeline of 22 ANDAs and 52 strengths.

The company’s manufacturing network includes:

• Formulation facilities: Atlanta, USA (USFDA-approved, DEA, TAA & BAA compliant) and Chhatral, Ahmedabad, India (WHO-GMP approved).
• API facilities: Two sites near Ahmedabad, India.

Senores also develops complex generics and manufactures critical care injectables and APIs for over 40 countries. Its R&D capabilities span three sites—one in the US and two in India.

Senores Pharma Share Price Performance

Senores Pharmaceuticals Limited was trading at ₹784.00, reflecting a gain of ₹20.35 or 2.66%. The stock opened at ₹800, with a previous close of ₹763.65, and moved within a day’s range of ₹768 to ₹800.

Read more: Best Pharma Stocks in December 2025.

Conclusion

The launch of Deferiprone Tablets in the US market strengthens Senores Pharmaceuticals’ presence in niche generics and demonstrates its ability to address specific therapeutic segments.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.